Evaluation of bisphenol A glucuronidation according to UGT1A1*28 polymorphism by a new LC-MS/MS assay

Toxicology

Volumn 292, Issue 1, 2012, Pages 33-41

  Trdan Lušin, Tina ^a   Roškar, Robert ^a   Mrhar, Aleš ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

28; Bisphenol A; Glucuronidation; Human organs; LC MS MS; Microsomes; UGT1A1

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; GLUCURONOSYLTRANSFERASE 1A1;

ACCURACY; ARTICLE; BODY WEIGHT; CLEARANCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DETOXIFICATION; DNA POLYMORPHISM; EVALUATION; GENOTYPE; GLUCURONIDATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE; ISOTOPE LABELING; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; LUNG; MASS SPECTROMETRY; MICHAELIS MENTEN KINETICS; MICROSOME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

CHROMATOGRAPHY, LIQUID; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MICROSOMES; PHENOLS; POLYMORPHISM, GENETIC; TANDEM MASS SPECTROMETRY;

EID: 84855298719     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.11.015     Document Type: Article

References (37)

1. Bae J.W., Choi C.I., Lee J.H., Jang C.G., Chung M.W., Lee S.Y. Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. Eur. J. Clin. Pharmacol. 2011, 67:39-45.
2. Ballesteros-Gomez A., Rubio S., Perez-Bendito D. Analytical methods for the determination of bisphenol A in food. J. Chromatogr. A 2009, 1216:449-469.
3. Bosma P.J., Chowdhury J.R., Bakker C., Gantla S., de Boer A., Oostra B.A., Lindhout D., Tytgat G.N., Jansen P.L., Oude Elferink R.P., et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 1995, 333:1171-1175.
4. Chapin R.E., Adams J., Boekelheide K., Gray L.E., Hayward S.W., Lees P.S., McIntyre B.S., Portier K.M., Schnorr T.M., Selevan S.G., Vandenbergh J.G., Woskie S.R. NTP-CERHR expert panel report on the reproductive and developmental toxicity of bisphenol A. Birth Defects Res. B: Dev. Reprod. Toxicol. 2008, 83:157-395.
5. Dekant W., Volkel W. Human exposure to bisphenol A by biomonitoring: methods, results and assessment of environmental exposures. Toxicol. Appl. Pharmacol. 2008, 228:114-134.
6. Elsby R., Maggs J.L., Ashby J., Park B.K. Comparison of the modulatory effects of human and rat liver microsomal metabolism on the estrogenicity of bisphenol A: implications for extrapolation to humans. J. Pharmacol. Exp. Ther. 2001, 297:103-113.
7. Ginsberg G., Rice D.C. Does rapid metabolism ensure negligible risk from bisphenol A. Environ. Health Perspect. 2009, 117:1639-1643.
8. Goodman J.E., McConnell E.E., Sipes I.G., Witorsch R.J., Slayton T.M., Yu C.J., Lewis A.S., Rhomberg L.R. An updated weight of the evidence evaluation of reproductive and developmental effects of low doses of bisphenol A. Crit. Rev. Toxicol. 2006, 36:387-457.
9. Goodman J.E., Witorsch R.J., McConnell E.E., Sipes I.G., Slayton T.M., Yu C.J., Franz A.M., Rhomberg L.R. Weight-of-evidence evaluation of reproductive and developmental effects of low doses of bisphenol A. Crit. Rev. Toxicol. 2009, 39:1-75.
10. Gray G.M., Cohen J.T., Cunha G., Hughes C., McConnell E.E., Rhomberg L., Sipes G., Mattison D. Weight of the evidence evaluation of low-dose reproductive and developmental effects of bisphenol A. Hum. Ecol. Risk Assess. 2004, 10:875-921.
11. Hanioka N., Naito T., Narimatsu S. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation. Chemosphere 2008, 74:33-36.
12. Hanioka N., Oka H., Nagaoka K., Ikushiro S., Narimatsu S. Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation. Arch. Toxicol. 2011, 11:1373-1381.
13. Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T., Fleming G.F., Vokes E.E., Schilsky R.L., Ratain M.J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002, 2:43-47.
14. Kang J.H., Kondo F., Katayama Y. Human exposure to bisphenol A. Toxicology 2006, 226:79-89.
15. Matthews J.B., Twomey K., Zacharewski T.R. In vitro and in vivo interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with estrogen receptors alpha and beta. Chem. Res. Toxicol. 2001, 14:149-157.
16. Mazur C.S., Kenneke J.F., Hess-Wilson J.K., Lipscomb J.C. Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab. Dispos. 2010, 38:2232-2238.
17. Ohno S., Nakajin S. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 2009, 37:32-40.
18. Peterkin V.C., Bauman J.N., Goosen T.C., Menning L., Man M.Z., Paulauskis J.D., Williams J.A., Myrand S.P. Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br. J. Clin. Pharmacol. 2007, 64:458-468.
19. Pritchett J.J., Kuester R.K., Sipes I.G. Metabolism of bisphenol a in primary cultured hepatocytes from mice, rats, and humans. Drug Metab. Dispos. 2002, 30:1180-1185.
20. Riedmaier S., Klein K., Hofmann U., Keskitalo J.E., Neuvonen P.J., Schwab M., Niemi M., Zanger U.M. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin. Pharmacol. Ther. 2010, 87:65-73.
21. Shimoyama S. Pharmacogenetics of irinotecan: an ethnicity-based prediction of irinotecan adverse events. World J. Gastrointest. Surg. 2010, 2:14-21.
22. Stahlhut R.W., Welshons W.V., Swan S.H. Bisphenol A data in NHANES suggest longer than expected half-life, substantial nonfood exposure, or both. Environ. Health Perspect. 2009, 117:784-789.
23. Strassburg C.P. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 2008, 9:703-715.
24. Teeguarden J.G., Waechter J.M., Clewell H.J., Covington T.R., Barton H.A. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. Toxicol. Sci. 2005, 85:823-838.
25. Teeguarden J.G., Calafat A.M., Ye X., Doerge D.R., Churchwell M.I., Gunawan R., Graham M.K. Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposure. Toxicol. Sci. 2011, 123:48-57.
26. Trdan Lusin T., Trontelj J., Mrhar A. Raloxifene glucuronidation in human intestine, kidney and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab. Dispos. 2011, 10.1124/dmd.111.041897.
27. Trdan T., Roskar R., Trontelj J., Ravnikar M., Mrhar A. Determination of raloxifene and its glucuronides in human urine by liquid chromatography-tandem mass spectrometry assay. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2011, 879:2323-2331.
28. Trontelj J., Marc J., Zavratnik A., Bogataj M., Mrhar A. Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 2009, 67:437-444.
29. Vandenberg L.N., Maffini M.V., Sonnenschein C., Rubin B.S., Soto A.M. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr. Rev. 2009, 30:75-95.
30. Vandenberg L.N., Chahoud I., Heindel J.J., Padmanabhan V., Paumgartten F.J., Schoenfelder G. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. Environ. Health Perspect. 2010, 118:1055-1070.
31. Volkel W., Colnot T., Csanady G.A., Filser J.G., Dekant W. Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem. Res. Toxicol. 2002, 15:1281-1287.
32. Volkel W., Bittner N., Dekant W. Quantitation of bisphenol A and bisphenol A glucuronide in biological samples by high performance liquid chromatography-tandem mass spectrometry. Drug Metab. Dispos. 2005, 33:1748-1757.
33. vom Saal F.S., Hughes C. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. Environ. Health Perspect. 2005, 113:926-933.
34. Willhite C.C., Ball G.L., McLellan C.J. Derivation of a bisphenol A oral reference dose (RfD) and drinking-water equivalent concentration. J. Toxicol. Environ. Health B Crit. Rev. 2008, 11:69-146.
35. Yamanaka H., Nakajima M., Katoh M., Yokoi T. Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab. Dispos. 2007, 35:1642-1648.
36. Yoder Graber A.L., Ramirez J., Innocenti F., Ratain M.J. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet. Genomics 2007, 17:619-627.
37. Zhang D., Cui D., Gambardella J., Ma L., Barros A., Wang L., Fu Y., Rahematpura S., Nielsen J., Donegan M., Zhang H., Humphreys W.G. Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab. Dispos. 2007, 35:2270-2280.